Other sideroblastic anemias
ICD-10 D64.3 is a billable code used to indicate a diagnosis of other sideroblastic anemias.
Sideroblastic anemia is a heterogeneous group of disorders characterized by the presence of ringed sideroblasts in the bone marrow. These disorders can be inherited or acquired and are marked by ineffective erythropoiesis and the accumulation of iron in the mitochondria of erythroid precursors. The acquired forms can result from various factors, including exposure to toxins, certain medications, or underlying diseases such as myelodysplastic syndromes. Patients typically present with symptoms of anemia, including fatigue, pallor, and weakness. Diagnosis is confirmed through blood tests showing microcytic anemia and a bone marrow biopsy revealing ringed sideroblasts. Treatment may involve addressing the underlying cause, iron chelation therapy, or vitamin B6 supplementation, depending on the specific type of sideroblastic anemia. Understanding the nuances of this condition is crucial for accurate coding and management.
Comprehensive blood work results, bone marrow biopsy reports, and treatment plans.
Diagnosis and management of sideroblastic anemia in patients with a history of exposure to toxins or medications.
Ensure that all laboratory findings are clearly documented to support the diagnosis.
Detailed patient history, physical examination findings, and any relevant imaging or lab results.
Evaluation of anemia in patients with chronic diseases or nutritional deficiencies.
Document any comorbid conditions that may contribute to anemia.
Used to evaluate anemia and monitor treatment response.
Document the reason for the CBC and any relevant findings.
Hematologists may require more detailed CBC interpretations.
Acquired sideroblastic anemia can be caused by exposure to toxins (like lead), certain medications (such as chloramphenicol), alcohol abuse, and underlying diseases like myelodysplastic syndromes.
